Ansermo Arthur, MD
Interventional Cardiology · Aiken, SCNPI 1720161151
Payments from drug & device makers
Across 552 payments — averaging $71.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$11K
- Abbott$5K
- Pfizer$4K
- Penumbra, Inc.$4K
- Boston Scientific$2K
- Cook Incorporated$2K
- plus $11K from 48 others
What the payments were for
- Speaking & faculty fees$14,18036%
- Travel & lodging$12,31231%
- Food & beverage$12,52832%
- Education$1981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$10,534
- AVEIR$4,199
- ELIQUIS$3,500
- Indigo System$2,280
- Indigo$1,574
- GORE CARDIOFORM Septal Occluder$1,125
- INGEVITY$1,121
- Zenith$1,120
- LifeVest$750
- Cook$740
- VersaCross Access Solution$500
- SYMPLICITY G3$400
- Zenith Spiral-Z$332
- Watchman$318
- AFX2 Bifurcated Endograft System$218
- Ovation iX Iliac Stent Graft$218
- FLOWTRIEVER CATHETER, S$163
- CT THROMBECTOMY SYSTEM KIT$163
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$151
- NEXLIZET$125
How this compares
$39,217 in reported general payments places this provider in the 75th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,108 | $981,295 |
| EntrestoSacubitril/Valsartan | 421 | $420,596 |
| XareltoRivaroxaban | 384 | $323,029 |
| BrilintaTicagrelor | 251 | $179,057 |
| Droxidopa | 23 | $91,395 |
| FarxigaDapagliflozin Propanediol | 78 | $72,242 |
| JardianceEmpagliflozin | 37 | $36,220 |
| VerquvoVericiguat | 11 | $18,729 |
| EdarbiAzilsartan Medoxomil | 40 | $18,077 |
| Repatha SureclickEvolocumab | 20 | $17,260 |
| Valsartan | 440 | $11,886 |
| Ranolazine ErRanolazine | 111 | $11,338 |
| Dofetilide | 81 | $9,614 |
| Metoprolol Succinate | 488 | $7,350 |
| NexletolBempedoic Acid | 12 | $6,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $3,979 | $981,2951,108 claims |
| NovartisEntresto | $653 | $420,596421 claims |
| Johnson & JohnsonXarelto | $11,095 | $323,029384 claims |
| AstraZenecaBrilinta, Farxiga | $398 | $251,299329 claims |
| Boehringer IngelheimJardiance | $11 | $36,22037 claims |
| MerckVerquvo | $211 | $18,72911 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $60 | $18,07740 claims |
| Esperion Therapeutics, Inc.Nexletol | $125 | $6,90412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Aiken
- Christine MillsAiken$27K
- Daniel SteinbergCharleston$1.1M
- Nicholas AmorosoPawleys Island$1.1M
- Robert LeonardiWest Columbia$881K
- Lars RunquistCharleston$861K
- Kurt BarringhausColumbia$536K
- Brian BrownSpartanburg$477K
- Josh DollGreenville$429K
- Thomas TodoranPawleys Island$316K
- Daniel GreenGreenville$256K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.